MX2019009658A - Anti-inflammatory compositions comprising irak and jak inhibitors. - Google Patents
Anti-inflammatory compositions comprising irak and jak inhibitors.Info
- Publication number
- MX2019009658A MX2019009658A MX2019009658A MX2019009658A MX2019009658A MX 2019009658 A MX2019009658 A MX 2019009658A MX 2019009658 A MX2019009658 A MX 2019009658A MX 2019009658 A MX2019009658 A MX 2019009658A MX 2019009658 A MX2019009658 A MX 2019009658A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- irak
- jak inhibitors
- compound
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000007306 turnover Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses compositions comprising compounds according to Formula I wherein R1, R2, and Cy are as defined herein, and a second compound having a JAK inhibiting activity. The present invention relates to composition, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases, allergic diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound of the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702603.0A GB201702603D0 (en) | 2017-02-17 | 2017-02-17 | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2018/053803 WO2018149925A1 (en) | 2017-02-17 | 2018-02-15 | Anti-inflammatory compositions comprising irak and jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009658A true MX2019009658A (en) | 2019-10-02 |
Family
ID=58486866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009658A MX2019009658A (en) | 2017-02-17 | 2018-02-15 | Anti-inflammatory compositions comprising irak and jak inhibitors. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3582775A1 (en) |
| JP (1) | JP2020507612A (en) |
| KR (1) | KR20190117672A (en) |
| CN (1) | CN110300586A (en) |
| AU (1) | AU2018221761A1 (en) |
| BR (1) | BR112019016949A2 (en) |
| CA (1) | CA3054652A1 (en) |
| GB (1) | GB201702603D0 (en) |
| MA (1) | MA47495A (en) |
| MX (1) | MX2019009658A (en) |
| PH (1) | PH12019501853A1 (en) |
| SG (1) | SG11201907492TA (en) |
| WO (1) | WO2018149925A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| CN113713083A (en) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | Pharmaceutical composition for treating alopecia |
| US20230271942A1 (en) * | 2020-08-07 | 2023-08-31 | Pharmablock Sciences (Nanjing), Inc. | Cdk9 inhibitor and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (en) | 2008-07-25 | 2016-09-05 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| TWI462920B (en) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| SI2863950T1 (en) | 2012-06-22 | 2018-10-30 | Galapagos Nv | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201518456D0 (en) * | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| WO2017106564A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
-
2017
- 2017-02-17 GB GBGB1702603.0A patent/GB201702603D0/en not_active Ceased
-
2018
- 2018-02-15 MA MA047495A patent/MA47495A/en unknown
- 2018-02-15 SG SG11201907492TA patent/SG11201907492TA/en unknown
- 2018-02-15 AU AU2018221761A patent/AU2018221761A1/en not_active Abandoned
- 2018-02-15 KR KR1020197027092A patent/KR20190117672A/en not_active Withdrawn
- 2018-02-15 WO PCT/EP2018/053803 patent/WO2018149925A1/en not_active Ceased
- 2018-02-15 MX MX2019009658A patent/MX2019009658A/en unknown
- 2018-02-15 CA CA3054652A patent/CA3054652A1/en not_active Abandoned
- 2018-02-15 JP JP2019544638A patent/JP2020507612A/en active Pending
- 2018-02-15 CN CN201880012183.5A patent/CN110300586A/en active Pending
- 2018-02-15 BR BR112019016949-0A patent/BR112019016949A2/en not_active Application Discontinuation
- 2018-02-15 EP EP18707866.2A patent/EP3582775A1/en not_active Withdrawn
-
2019
- 2019-08-08 PH PH12019501853A patent/PH12019501853A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018149925A1 (en) | 2018-08-23 |
| KR20190117672A (en) | 2019-10-16 |
| BR112019016949A2 (en) | 2020-05-26 |
| EP3582775A1 (en) | 2019-12-25 |
| CA3054652A1 (en) | 2018-08-23 |
| JP2020507612A (en) | 2020-03-12 |
| AU2018221761A1 (en) | 2019-10-03 |
| SG11201907492TA (en) | 2019-09-27 |
| MA47495A (en) | 2019-12-25 |
| PH12019501853A1 (en) | 2020-06-15 |
| GB201702603D0 (en) | 2017-04-05 |
| CN110300586A (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550230A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2013012281A (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases. | |
| PH12020552160A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| PH12020550725B1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| TW201613873A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2021013803A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases. | |
| MX2023011282A (en) | C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors. | |
| NZ702480A (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| NZ738187A (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| PH12017501160A1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| TW201613601A (en) | Pharmaceutical compositions for the treatment of inflammatory disorders | |
| UY32741A (en) | CYCLOPROPANCARBOXYL ACID [1,2,4] TRIAZOL [1,5-a] PIRIDIN-2-IL-AMIDA USEFUL FOR THE TREATMENT OF INFLAMMATORY AND DEGENERATIVE DISEASES | |
| PH12021552375A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2018001925A (en) | Compositions comprising tricyclic heterocyclic compounds. | |
| PH12018500827A1 (en) | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors | |
| PH12021552376A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12021552680A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases | |
| NZ803938A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders. |